Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2011 Mar;56(3):491-4. doi: 10.1002/pbc.22868.

Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

Author information

1
Department of Hematology-Oncology, Children's Health Care of Atlanta, Emory University, Atlanta, Georgia, USA.

Abstract

Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression-free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy.

PMID:
21072819
DOI:
10.1002/pbc.22868
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center